Published in 2022

BOOK: RNA Delivery Function for Anticancer Therapeutics ByLoutfy H. Madkour

Cancer Epigenetic Mechanisms Circulating MiRNAs Therapeutic Targets and Novel DNA-Damaging Cancer Therapies

Authors: Loutfy H. Madkour

Journal: CRC Press

Description:

This book presents an overview of the current status of translating the RNAi cancer therapeutics in the clinic, a brief description of the biological barriers in drug delivery, and the roles of imaging in aspects of administration route, systemic circulation, and cellular barriers for the clinical translation of RNAi cancer therapeutics, and with partial content for discussing the safety concerns. It then focuses on imaging-guided delivery of RNAi therapeutics in preclinical development, including the basic principles of different imaging modalities, and their advantages and limitations for biological imaging. With growing number of RNAi therapeutics entering the clinic, various imaging methods will play an important role in facilitating the translation of RNAi cancer therapeutics from bench to bedside. RNAi technique has become a powerful tool for basic research to selectively knock down gene expression in vitro and in vivo. Our scientific and industrial communities have started to develop RNAi therapeutics as the next class of drugs for treating a variety of genetic disorders, such as cancer and other diseases that are particularly hard to address with current treatment strategies. Key Features　 Provides　insight　into　the　current　advances　and　hurdles　of　RNAi　therapeutics.　　 Accelerates　RNAi,　miRNAs, and siRNA　drug　development　for cancer therapy　from　bench　to　bedside.　 Addresses　various modifications and　novel　delivery　strategies for miRNAs,　piRNAs　and siRNA delivery　in　anticancer therapeutics.　　 Explores the need for the interaction　of　hematologists,cell　biologists,　immunologists, and material　scientists　in the development of 　novel　cancer therapies. 　 Describes the　current status　of clinical trials related to miRNA and siRNA-based cancer therapy　 Presents　remaining issues that need to be overcome to establish　successful therapies.　

Published in 2022

BOOK: Nanoparticle-Based Drug Delivery in Cancer Treatment

Bioscience Engineering Technology Cancer

Authors: Loutfy H. Madkour

Journal: CRC Press

Description:

The careful choice of nanoparticles as targets and in drug delivery routes enhances therapeutic efficacy in cancer. Nanoparticle-Based Drug Delivery in Cancer Treatment discusses nanotechnological developments of interfering RNA-based nanoparticles, delivery vehicles, and validated therapeutic RNAi–molecular target interactions and explains the results of clinical and preclinical trials. The book also gives strategies for universal methods of constructing hybrid organic–inorganic nanomaterials that can be widely applied in the biomedical field.

Published in 2022

Auranofin and Baicalin Inhibit Clostridioides difficile Growth and Sporulation: An In vitro Study

Authors: Lamiaa A. Madkour

Journal: Journal of Pure and Applied Microbiology

Published in 2022

Plasma circPTPN22 and its potential target microRNA-200a-3p as novel diagnostic biomarkers in systemic lupus erythematosus patients

Authors: Hagar L. Mowafy, Maha M. Kotb, Kamal M. Hanna, Fatema T. Elgengehy, Lamiaa A. Madkour

Journal: The Egyptian Rheumatologist

Published in 2021

Biotechnology of Nanostructures Micronutrients Vitamins for Human Health

Biotechnology Nanostructures Micronutrients Vitamins for Human

Authors: Loutfy H. Madkour

Journal: J Biomed Res Environ Sci. 2021 May 22; 2(5): 358-371.

Description:

Nowadays, nanotechnology is used as a way to increase bioavailability and decrease the side effects of drugs and nutrients. Micronutrients and nutraceuticals such as vitamins, carotenoids, polyunsaturated fatty acids and polyphenols are classes of food ingredients that are essential for human health and well-being. These compounds are rarely added purely to the targeted food application but rather in encapsulated, solid, dry product forms with added functionalities such as improved stability, bioavailability or handling. Development of new strategies, like nanocarriers, that help to promote the access of neuroprotective molecules to the brain, is needed for providing more effective therapies for the disorders of the Central Nervous System (CNS). Polymer–lipid hybrid nanoparticles, encapsulating vitamin D3 and vitamin K2, with improved features in terms of stability, loading and mucoadhesiveness were produced for potential nutraceutical and pharmaceutical applications. Recently, nanoformulations that include nanovesicles, solid-lipid nanoparticles, nanostructured lipid carriers, nanoemulsions, and polymeric nanoparticles have shown promising outcomes in improving the efficacy and bioavailability of vitamin E. Active targeting of nanoparticles loaded with vitamin D to cancer cells.

Published in 2021

Nucleic Acids (DNA/RNA) as Nanoparticles Structures for siRNA Delivery Medical Applications

(DNA/RNA) Nanoparticles Structures siRNA Delivery Medical Applications

Authors: Loutfy H Madkour

Journal: Journal of Pharmaceutics and Drug Research JPDR, 4(2): 480-503

Description:

Engineered design of synthetic DNA/RNA molecules can generate pre-defined structures that can easily self-assemble to form nanoparticles with multiple functionalities. The identification and selection of highly potent siRNA sequences has already been accomplished for many gene targets, and the synthesis of siRNAs on a large scale has been achieved. The field of oligonucleotide-based nanotechnology for biomedical applications is just emerging, but will play an important role in the delivery of siRNA. In particular, oligonucleotide-based structural RNAi systems described in this chapter are promising as a new generation of gene delivery carriers for cancer therapy. RNA interference (RNAi) is a gene regulation mechanism initiated by RNA molecules that enables sequence-specific gene silencing by promoting degradation of specific mRNAs. Molecular therapy using small interfering RNA (siRNA) has shown great therapeutic potential for diseases caused by abnormal gene overexpression or mutation. The major challenges to application of siRNA therapeutics include the stability and effective delivery of siRNA in vivo. In this chapter, we discuss recent advances in nanoparticle-mediated siRNA delivery systems and the application of these systems in clinical trials for cancer therapy. Furthermore, we offer perspectives on future applications of siRNA therapeutics.

Published in 2021

Imaging modalities delivery of RNAi therapeutics in cancer therapy and clinical applications

Imaging modalities delivery RNAi therapeutics cancer therapy

Authors: Loutfy H Madkour*

Journal: J Radiol Oncol. 2021; 5: 005-034.

Description:

The RNA interference (RNAi) technique is a new modality for cancer therapy, and several candidates are being tested clinically. Nanotheranostics is a rapidly growing field combining disease diagnosis and therapy, which ultimately may add in the development of ‘personalized medicine’. Technologies on theranostic nanomedicines has been discussed. We designed and developed bioresponsive and fluorescent hyaluronic acid-iodixanol nanogels (HAI-NGs) for targeted X-ray computed tomography (CT) imaging and chemotherapy of MCF-7 human breast tumors. HAI-NGs were obtained with a small size of ca. 90 nm, bright green fluorescence and high serum stability from hyaluronic acid-cystamine-tetrazole and reductively degradable polyiodixanol-methacrylate via nanoprecipitation and a photo-click crosslinking reaction. This chapter presents an over view of the current status of translating the RNAi cancer therapeutics in the clinic, a brief description of the biological barriers in drug delivery, and the roles of imaging in aspects of administration route, systemic circulation, and cellular barriers for the clinical translation of RNAi cancer therapeutics, and with partial content for discussing the safety concerns. Finally, we focus on imaging-guided delivery of RNAi therapeutics in preclinical development, including the basic principles of different imaging modalities, and their advantages and limitations for biological imaging. With growing number of RNAi therapeutics entering the clinic, various imaging methods will play an important role in facilitating the translation of RNAi cancer therapeutics from bench to bedside.

Published in 2021

Metal Nanoparticles and their Safety Processing in Functional Foods

Metal Nanoparticles safety processing functional foods

Authors: Loutfy H. Madkour

Journal: Journal of Chemical Science and Chemical Engineering

Description:

A Safety of nanotechnology in food industries has been discussed. Different nanomaterials (NMs) such as nanopowders, nanotubes, nano-fibers, quantum dots, and metal and metal-oxide nanoparticles are globally produced in large quantities due to their broad applicability in food-related industries. We present some uses of nanoparticles in food and related industries and their possible side effects. The various aspects of nanoparticles and their impact on human exposure, safety, and environmental concerns have been discussed. ZnO NPs are listed as a kind of safe substance by the FDA. The safety of nanostructured synthetic amorphous silica (SAS) as a food additive (E 551) has been discussed. and has always been produced by the same two production methods. Bioavailability increases for iron of nanometer size. The characteristics of broad spectrum of activity against food pathogens of silver nanostructures …

Published in 2021

Biotechnology of Nanostructures Micronutrients Vitamins for Human Health

Biotechnology Nanostructures Micronutrients Vitamins

Authors: Loutfy H Madkour

Journal: J Biomed Res Environ Sci,

Description:

Nowadays, nanotechnology is used as a way to increase bioavailability and decrease the side effects of drugs and nutrients. Micronutrients and nutraceuticals such as vitamins, carotenoids, polyunsaturated fatty acids and polyphenols are classes of food ingredients that are essential for human health and well-being. These compounds are rarely added purely to the targeted food application but rather in encapsulated, solid, dry product forms with added functionalities such as improved stability, bioavailability or handling. Development of new strategies, like nanocarriers, that help to promote the access of neuroprotective molecules to the brain, is needed for providing more effective therapies for the disorders of the Central Nervous System (CNS). Polymer–lipid hybrid nanoparticles, encapsulating vitamin D3 and vitamin K2, with improved features in terms of stability, loading and mucoadhesiveness were produced for potential nutraceutical and pharmaceutical applications. Recently, nanoformulations that include nanovesicles, solid-lipid nanoparticles, nanostructured lipid carriers, nanoemulsions, and polymeric nanoparticles have shown promising outcomes in improving the effi cacy and bioavailability of vitamin E. Active targeting of nanoparticles loaded with vitamin D to cancer cells

Published in 2021

Recent Targeted of siRNA Delivery Vehicles for Cancer Therapy

Recent Targeted siRNA Delivery Vehicles Cancer Therapy

Authors: Loutfy H Madkour

Journal: Biomed J Sci & Tech Res 34(4)-2021. BJSTR. MS.ID.005577.

Description:

Recent progress in RNA biology has broadened the scope of therapeutic targets of RNA drugs for cancer therapy. However, RNA drugs, typically small interfering RNAs (siRNAs), are rapidly degraded by RNases and filtrated in the kidney, thereby requiring a delivery vehicle for efficient transport to the target cells. To date, various delivery formulations have been developed from cationic lipids, polymers, and/or inorganic nanoparticles for systemic delivery of siRNA to solid tumors. This research article describes the current status of clinical trials related to siRNA-based cancer therapy, as well as the remaining issues that need to be overcome to establish a successful therapy. It, then introduces various promising design strategies of delivery vehicles for stable and targeted siRNA delivery, including the prospects for future design. The current major strategies to design delivery vehicles for systemic siRNA delivery involve the construction of multimolecular assemblies from more than dozens of monomer components, including siRNA. The success of RNAi-based cancer therapy is closely associated with tumor biology as well as architecture of delivery vehicles. Tumor cell plasticity evokes a resistance mechanism against clinical treatments, and cancer stem cells are gradually being identified as the root of cancer recurrence. New target RNA genes should be discovered to increase apoptosis in cancer cells and simultaneously reduce side effects in normal and healthy cells. Multidisciplinary research studies will guide the development of highly effective and safer RNAi-based drugs in clinical trials. Keywords: RNAi; siRNA Delivery; Polyion Complex Micelle; Systemic Administration; Cancer Therapy